| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ethics Committees, Research | 15 | 2024 | 196 | 5.130 |
Why?
|
| Clinical Trials as Topic | 26 | 2024 | 8002 | 2.880 |
Why?
|
| Biomedical Research | 21 | 2024 | 3429 | 2.780 |
Why?
|
| Information Dissemination | 13 | 2024 | 1126 | 2.070 |
Why?
|
| Research Subjects | 8 | 2024 | 249 | 2.030 |
Why?
|
| T-Lymphocytes | 66 | 2006 | 10194 | 1.850 |
Why?
|
| Ethics, Research | 7 | 2022 | 176 | 1.630 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 27 | 1994 | 898 | 1.480 |
Why?
|
| Patient Selection | 9 | 2024 | 4244 | 1.440 |
Why?
|
| Authorship | 3 | 2019 | 284 | 1.430 |
Why?
|
| Informed Consent | 7 | 2023 | 1008 | 1.400 |
Why?
|
| Scientific Misconduct | 2 | 2024 | 74 | 1.320 |
Why?
|
| Patient Participation | 4 | 2023 | 1445 | 1.320 |
Why?
|
| Tacrolimus | 32 | 2003 | 733 | 1.260 |
Why?
|
| Lymphocyte Activation | 44 | 2003 | 5485 | 1.230 |
Why?
|
| Confidentiality | 7 | 2024 | 609 | 1.220 |
Why?
|
| Polyenes | 21 | 1996 | 68 | 1.070 |
Why?
|
| Cyclosporine | 21 | 2003 | 778 | 1.020 |
Why?
|
| Research Design | 9 | 2023 | 6180 | 0.990 |
Why?
|
| Human Experimentation | 2 | 2017 | 123 | 0.990 |
Why?
|
| Receptors, Immunologic | 20 | 1994 | 1410 | 0.980 |
Why?
|
| Acupuncture Therapy | 3 | 2024 | 486 | 0.900 |
Why?
|
| Ethics Committees | 1 | 2023 | 51 | 0.890 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2023 | 25 | 0.840 |
Why?
|
| Disabled Persons | 2 | 2022 | 1226 | 0.830 |
Why?
|
| Delphi Technique | 2 | 2023 | 846 | 0.820 |
Why?
|
| Federal Government | 1 | 2024 | 267 | 0.810 |
Why?
|
| Behavioral Research | 1 | 2022 | 52 | 0.800 |
Why?
|
| Clinical Protocols | 2 | 2020 | 1440 | 0.790 |
Why?
|
| Ethical Review | 2 | 2019 | 27 | 0.790 |
Why?
|
| Phosphoprotein Phosphatases | 15 | 1996 | 329 | 0.760 |
Why?
|
| Civil Rights | 1 | 2022 | 132 | 0.720 |
Why?
|
| Achievement | 1 | 2022 | 288 | 0.710 |
Why?
|
| Immunosuppressive Agents | 22 | 2005 | 4176 | 0.710 |
Why?
|
| Calcineurin | 17 | 2003 | 229 | 0.710 |
Why?
|
| Privacy | 2 | 2024 | 233 | 0.690 |
Why?
|
| Compensation and Redress | 1 | 2019 | 66 | 0.660 |
Why?
|
| Journalism, Medical | 1 | 2020 | 73 | 0.660 |
Why?
|
| Calmodulin-Binding Proteins | 14 | 1996 | 233 | 0.660 |
Why?
|
| Disclosure | 3 | 2023 | 748 | 0.650 |
Why?
|
| Triage | 2 | 2023 | 986 | 0.650 |
Why?
|
| Antigens, CD | 22 | 2001 | 4001 | 0.640 |
Why?
|
| Truth Disclosure | 1 | 2023 | 434 | 0.640 |
Why?
|
| Pandemics | 7 | 2024 | 8656 | 0.630 |
Why?
|
| Government Regulation | 4 | 2018 | 524 | 0.630 |
Why?
|
| Actins | 5 | 2006 | 2050 | 0.620 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2020 | 793 | 0.610 |
Why?
|
| Editorial Policies | 2 | 2020 | 458 | 0.610 |
Why?
|
| Motivation | 5 | 2020 | 2006 | 0.590 |
Why?
|
| Dental Care | 1 | 2021 | 285 | 0.590 |
Why?
|
| Membrane Glycoproteins | 16 | 1999 | 3701 | 0.590 |
Why?
|
| Humans | 194 | 2024 | 761596 | 0.590 |
Why?
|
| Ecosystem | 1 | 2022 | 490 | 0.590 |
Why?
|
| Attitude | 1 | 2022 | 775 | 0.580 |
Why?
|
| Clinical Competence | 3 | 2022 | 4793 | 0.580 |
Why?
|
| Social Values | 1 | 2018 | 225 | 0.580 |
Why?
|
| Universal Precautions | 1 | 2017 | 34 | 0.580 |
Why?
|
| Jurkat Cells | 13 | 2006 | 740 | 0.550 |
Why?
|
| Phlebotomy | 1 | 2017 | 137 | 0.540 |
Why?
|
| Antigens, Surface | 13 | 1991 | 1606 | 0.540 |
Why?
|
| Morals | 4 | 2022 | 289 | 0.530 |
Why?
|
| Receptors, Antigen, T-Cell | 20 | 2001 | 2547 | 0.510 |
Why?
|
| Consent Forms | 3 | 2021 | 55 | 0.490 |
Why?
|
| Interleukin-2 | 28 | 2006 | 1889 | 0.490 |
Why?
|
| Databases, Factual | 4 | 2023 | 7968 | 0.480 |
Why?
|
| Duty to Warn | 1 | 2014 | 30 | 0.470 |
Why?
|
| Facility Regulation and Control | 1 | 2014 | 24 | 0.470 |
Why?
|
| Information Storage and Retrieval | 2 | 2020 | 819 | 0.470 |
Why?
|
| United States Public Health Service | 1 | 2014 | 31 | 0.470 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 703 | 0.460 |
Why?
|
| Registries | 4 | 2023 | 8225 | 0.460 |
Why?
|
| Publishing | 3 | 2024 | 833 | 0.460 |
Why?
|
| Signal Transduction | 32 | 2003 | 23447 | 0.460 |
Why?
|
| Information Systems | 1 | 2016 | 396 | 0.450 |
Why?
|
| Nuclear Proteins | 9 | 2002 | 5799 | 0.450 |
Why?
|
| Rare Diseases | 1 | 2019 | 622 | 0.450 |
Why?
|
| Tacrolimus Binding Proteins | 16 | 2002 | 194 | 0.450 |
Why?
|
| Receptors, CXCR4 | 3 | 2003 | 727 | 0.440 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 1702 | 0.440 |
Why?
|
| Decision Making | 4 | 2022 | 3929 | 0.440 |
Why?
|
| Gelsolin | 2 | 2006 | 189 | 0.430 |
Why?
|
| Travel | 1 | 2019 | 796 | 0.430 |
Why?
|
| Carrier Proteins | 18 | 2003 | 4937 | 0.420 |
Why?
|
| Membrane Microdomains | 2 | 2006 | 206 | 0.420 |
Why?
|
| Antigens, Differentiation | 9 | 1999 | 909 | 0.420 |
Why?
|
| Phosphotyrosine | 6 | 2006 | 456 | 0.420 |
Why?
|
| Heat-Shock Proteins | 11 | 1996 | 795 | 0.410 |
Why?
|
| Language | 2 | 2021 | 1543 | 0.410 |
Why?
|
| Leadership | 1 | 2022 | 1385 | 0.400 |
Why?
|
| Cyclic AMP | 6 | 2002 | 1463 | 0.400 |
Why?
|
| Data Collection | 1 | 2021 | 3322 | 0.390 |
Why?
|
| Patient Advocacy | 1 | 2014 | 360 | 0.390 |
Why?
|
| Tetradecanoylphorbol Acetate | 10 | 2003 | 817 | 0.380 |
Why?
|
| Hybridomas | 15 | 2002 | 442 | 0.380 |
Why?
|
| Organizational Innovation | 1 | 2014 | 537 | 0.380 |
Why?
|
| Advisory Committees | 2 | 2017 | 787 | 0.370 |
Why?
|
| Conflict of Interest | 2 | 2015 | 554 | 0.360 |
Why?
|
| Communication | 2 | 2022 | 3875 | 0.350 |
Why?
|
| Curriculum | 2 | 2022 | 3743 | 0.350 |
Why?
|
| Research Support as Topic | 3 | 2021 | 697 | 0.350 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2000 | 1076 | 0.340 |
Why?
|
| United States | 21 | 2024 | 72340 | 0.340 |
Why?
|
| Nurse Clinicians | 1 | 2009 | 30 | 0.330 |
Why?
|
| Trust | 1 | 2014 | 530 | 0.330 |
Why?
|
| Bone Marrow Transplantation | 13 | 2005 | 2693 | 0.330 |
Why?
|
| DNA-Binding Proteins | 15 | 2002 | 9610 | 0.310 |
Why?
|
| Sirolimus | 22 | 2005 | 1533 | 0.300 |
Why?
|
| Protein-Tyrosine Kinases | 9 | 2003 | 2425 | 0.300 |
Why?
|
| Policy | 3 | 2023 | 509 | 0.300 |
Why?
|
| Program Development | 1 | 2014 | 1297 | 0.300 |
Why?
|
| Consensus | 3 | 2023 | 3124 | 0.290 |
Why?
|
| NFATC Transcription Factors | 8 | 2006 | 389 | 0.290 |
Why?
|
| Computer Security | 2 | 2020 | 261 | 0.280 |
Why?
|
| Cancer Care Facilities | 2 | 2009 | 422 | 0.280 |
Why?
|
| Microtubules | 4 | 2000 | 1074 | 0.270 |
Why?
|
| Transfection | 15 | 2003 | 5774 | 0.270 |
Why?
|
| Cytoskeleton | 4 | 2006 | 1170 | 0.270 |
Why?
|
| Universities | 1 | 2011 | 993 | 0.260 |
Why?
|
| T-Lymphocytes, Cytotoxic | 8 | 1994 | 1784 | 0.260 |
Why?
|
| Risk Management | 1 | 2009 | 558 | 0.260 |
Why?
|
| Models, Theoretical | 2 | 2014 | 3575 | 0.250 |
Why?
|
| Financing, Organized | 2 | 2019 | 204 | 0.250 |
Why?
|
| Tyrosine | 6 | 2001 | 1440 | 0.250 |
Why?
|
| Research Personnel | 5 | 2024 | 588 | 0.240 |
Why?
|
| Amino Acid Isomerases | 6 | 1995 | 31 | 0.240 |
Why?
|
| United States Office of Research Integrity | 1 | 2024 | 9 | 0.240 |
Why?
|
| Calcium | 11 | 2003 | 5722 | 0.230 |
Why?
|
| Hot Flashes | 2 | 2024 | 330 | 0.230 |
Why?
|
| Educational Status | 2 | 2022 | 2522 | 0.230 |
Why?
|
| Faculty, Dental | 1 | 2024 | 59 | 0.230 |
Why?
|
| Patient Compliance | 1 | 2014 | 2690 | 0.220 |
Why?
|
| Molecular Sequence Data | 22 | 2003 | 17635 | 0.220 |
Why?
|
| Republic of Korea | 2 | 2024 | 590 | 0.220 |
Why?
|
| Transcriptional Activation | 7 | 2006 | 1756 | 0.220 |
Why?
|
| Apoptosis | 5 | 2003 | 9490 | 0.220 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 5127 | 0.220 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 1996 | 435 | 0.220 |
Why?
|
| Cytochalasin D | 1 | 2003 | 91 | 0.220 |
Why?
|
| Feasibility Studies | 3 | 2023 | 5247 | 0.220 |
Why?
|
| Cytoplasm | 7 | 1999 | 1510 | 0.210 |
Why?
|
| Up-Regulation | 5 | 2003 | 4125 | 0.210 |
Why?
|
| Checklist | 2 | 2024 | 827 | 0.210 |
Why?
|
| Chemokines, C | 1 | 2002 | 10 | 0.210 |
Why?
|
| Qualitative Research | 2 | 2024 | 3025 | 0.210 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2003 | 187 | 0.210 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2003 | 1899 | 0.200 |
Why?
|
| Phosphoproteins | 7 | 2001 | 2448 | 0.200 |
Why?
|
| Biological Specimen Banks | 2 | 2020 | 783 | 0.200 |
Why?
|
| International Cooperation | 2 | 2020 | 1422 | 0.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2001 | 2898 | 0.200 |
Why?
|
| Ligases | 1 | 2003 | 333 | 0.200 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 4 | 2003 | 69 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2003 | 4514 | 0.190 |
Why?
|
| Protein Kinase C | 6 | 2003 | 1202 | 0.190 |
Why?
|
| Antigens, CD7 | 1 | 2001 | 29 | 0.190 |
Why?
|
| Amino Acid Sequence | 17 | 2003 | 13446 | 0.190 |
Why?
|
| Cell Line | 20 | 2003 | 15601 | 0.190 |
Why?
|
| Public Opinion | 2 | 2016 | 484 | 0.190 |
Why?
|
| Trans-Activators | 3 | 2001 | 2856 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 28 | 2006 | 9177 | 0.180 |
Why?
|
| Ethical Relativism | 1 | 2020 | 5 | 0.180 |
Why?
|
| Milk Proteins | 1 | 2001 | 163 | 0.180 |
Why?
|
| Membrane Fusion | 1 | 2002 | 266 | 0.180 |
Why?
|
| Response Elements | 1 | 2002 | 309 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 7391 | 0.180 |
Why?
|
| Dentistry | 1 | 2021 | 117 | 0.180 |
Why?
|
| Cultural Diversity | 1 | 2024 | 369 | 0.180 |
Why?
|
| Phosphorylation | 11 | 2006 | 8321 | 0.170 |
Why?
|
| Immunoconjugates | 2 | 1999 | 953 | 0.170 |
Why?
|
| Blood Cells | 2 | 2017 | 305 | 0.170 |
Why?
|
| Gene Expression Regulation | 8 | 2003 | 11904 | 0.170 |
Why?
|
| Recycling | 1 | 2019 | 16 | 0.170 |
Why?
|
| China | 2 | 2024 | 2374 | 0.170 |
Why?
|
| United States Dept. of Health and Human Services | 2 | 2017 | 88 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2001 | 641 | 0.170 |
Why?
|
| Beneficence | 1 | 2019 | 54 | 0.160 |
Why?
|
| Animals | 64 | 2005 | 168475 | 0.160 |
Why?
|
| Workflow | 1 | 2024 | 851 | 0.160 |
Why?
|
| Publication Bias | 1 | 2020 | 160 | 0.160 |
Why?
|
| Cooperative Behavior | 3 | 2017 | 1505 | 0.160 |
Why?
|
| Cloning, Molecular | 7 | 2003 | 4174 | 0.160 |
Why?
|
| Dyneins | 1 | 1999 | 124 | 0.160 |
Why?
|
| Internationality | 1 | 2024 | 1001 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2023 | 617 | 0.160 |
Why?
|
| Organizational Case Studies | 1 | 2019 | 301 | 0.160 |
Why?
|
| Depsipeptides | 1 | 1999 | 95 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 1 | 2003 | 1069 | 0.150 |
Why?
|
| Enzyme Activation | 8 | 2003 | 3597 | 0.150 |
Why?
|
| Hydroxychloroquine | 1 | 2022 | 426 | 0.150 |
Why?
|
| Organizational Culture | 2 | 2014 | 509 | 0.150 |
Why?
|
| Chemokines | 1 | 2002 | 959 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2009 | 2775 | 0.150 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2019 | 115 | 0.150 |
Why?
|
| Health Priorities | 2 | 2021 | 374 | 0.150 |
Why?
|
| Gene Expression | 6 | 2006 | 7581 | 0.150 |
Why?
|
| Population Dynamics | 1 | 2020 | 307 | 0.150 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 4 | 2003 | 93 | 0.140 |
Why?
|
| Leukapheresis | 1 | 2017 | 134 | 0.140 |
Why?
|
| Ribosomal Protein S6 Kinases | 6 | 1995 | 203 | 0.140 |
Why?
|
| Hypotension | 1 | 2023 | 879 | 0.140 |
Why?
|
| Kinetics | 9 | 2002 | 6374 | 0.140 |
Why?
|
| Chromosomes | 1 | 2000 | 578 | 0.140 |
Why?
|
| Protein Kinases | 3 | 1992 | 1608 | 0.140 |
Why?
|
| Personal Autonomy | 1 | 2019 | 304 | 0.140 |
Why?
|
| Ovarian Neoplasms | 2 | 2024 | 4878 | 0.140 |
Why?
|
| Cell Polarity | 1 | 2000 | 636 | 0.140 |
Why?
|
| Cytoskeletal Proteins | 2 | 2000 | 1342 | 0.140 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 1998 | 218 | 0.140 |
Why?
|
| Plant Proteins | 1 | 1999 | 370 | 0.140 |
Why?
|
| Recombinant Proteins | 12 | 2000 | 6534 | 0.140 |
Why?
|
| Research Report | 1 | 2020 | 367 | 0.140 |
Why?
|
| Cricetinae | 5 | 1999 | 2423 | 0.140 |
Why?
|
| Sialoglycoproteins | 5 | 2002 | 315 | 0.140 |
Why?
|
| Serum | 1 | 2017 | 209 | 0.130 |
Why?
|
| Causality | 1 | 2022 | 1242 | 0.130 |
Why?
|
| Bucladesine | 3 | 2002 | 118 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 11 | 1999 | 6131 | 0.130 |
Why?
|
| Interleukin-3 | 2 | 1994 | 425 | 0.130 |
Why?
|
| Body Fluids | 1 | 2017 | 320 | 0.130 |
Why?
|
| Cell Communication | 4 | 1993 | 1657 | 0.130 |
Why?
|
| Child | 5 | 2023 | 80158 | 0.130 |
Why?
|
| Orthopedics | 1 | 2024 | 898 | 0.130 |
Why?
|
| Oral Health | 1 | 2021 | 492 | 0.120 |
Why?
|
| Gift Giving | 1 | 2015 | 76 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 3 | 2003 | 110 | 0.120 |
Why?
|
| Public Health | 4 | 2024 | 2669 | 0.120 |
Why?
|
| Moral Obligations | 1 | 2016 | 93 | 0.120 |
Why?
|
| Peptidylprolyl Isomerase | 6 | 1995 | 97 | 0.120 |
Why?
|
| CHO Cells | 4 | 1999 | 1387 | 0.120 |
Why?
|
| Cytokines | 8 | 2000 | 7396 | 0.120 |
Why?
|
| Graft vs Host Disease | 10 | 2005 | 3029 | 0.120 |
Why?
|
| Eye Proteins | 1 | 1998 | 633 | 0.120 |
Why?
|
| Base Sequence | 11 | 2001 | 12441 | 0.120 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 1386 | 0.120 |
Why?
|
| HIV-1 | 2 | 2002 | 6863 | 0.120 |
Why?
|
| Capacity Building | 1 | 2017 | 258 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 3617 | 0.120 |
Why?
|
| Organizational Policy | 1 | 2017 | 432 | 0.120 |
Why?
|
| Safety | 3 | 2009 | 1149 | 0.110 |
Why?
|
| Social Control, Formal | 1 | 2014 | 108 | 0.110 |
Why?
|
| Mice | 38 | 2005 | 81539 | 0.110 |
Why?
|
| Plasma | 1 | 2017 | 586 | 0.110 |
Why?
|
| Health Care Sector | 1 | 2015 | 195 | 0.110 |
Why?
|
| Transcription Factors | 8 | 2002 | 12130 | 0.110 |
Why?
|
| Blood Proteins | 1 | 1998 | 1173 | 0.110 |
Why?
|
| Mast Cells | 3 | 1995 | 1392 | 0.110 |
Why?
|
| Protein Binding | 7 | 2003 | 9353 | 0.100 |
Why?
|
| RNA, Messenger | 12 | 2003 | 12794 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 1 | 1995 | 304 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3086 | 0.100 |
Why?
|
| Specimen Handling | 1 | 2017 | 702 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2001 | 1898 | 0.100 |
Why?
|
| Reward | 1 | 2019 | 971 | 0.100 |
Why?
|
| Cell Degranulation | 1 | 1993 | 277 | 0.100 |
Why?
|
| Policy Making | 1 | 2016 | 542 | 0.100 |
Why?
|
| Receptors, Leukocyte-Adhesion | 2 | 1991 | 52 | 0.100 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 8 | 1991 | 377 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2021 | 8633 | 0.100 |
Why?
|
| Drugs, Investigational | 1 | 2014 | 212 | 0.100 |
Why?
|
| Antibody Affinity | 1 | 1992 | 246 | 0.100 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2003 | 1741 | 0.100 |
Why?
|
| Public Policy | 1 | 2016 | 559 | 0.090 |
Why?
|
| Transplantation Immunology | 1 | 1993 | 532 | 0.090 |
Why?
|
| Plasmids | 3 | 1993 | 2269 | 0.090 |
Why?
|
| Glycoproteins | 1 | 1999 | 2203 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2003 | 10766 | 0.090 |
Why?
|
| Detergents | 2 | 2006 | 236 | 0.090 |
Why?
|
| Equipment and Supplies | 1 | 2014 | 273 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-vav | 2 | 2003 | 91 | 0.090 |
Why?
|
| Precipitin Tests | 3 | 1999 | 813 | 0.090 |
Why?
|
| Income | 1 | 2020 | 1877 | 0.090 |
Why?
|
| Cell Line, Transformed | 4 | 2002 | 866 | 0.090 |
Why?
|
| Protein Processing, Post-Translational | 2 | 1998 | 1974 | 0.090 |
Why?
|
| Enzyme Precursors | 2 | 2001 | 170 | 0.090 |
Why?
|
| Drug Resistance | 3 | 1995 | 1596 | 0.090 |
Why?
|
| Dihydropyridines | 1 | 1990 | 67 | 0.090 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 5337 | 0.090 |
Why?
|
| Psychiatry | 1 | 2023 | 1693 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 3 | 2003 | 3792 | 0.090 |
Why?
|
| Pyrans | 1 | 1990 | 49 | 0.090 |
Why?
|
| COS Cells | 2 | 2003 | 1130 | 0.090 |
Why?
|
| Academic Medical Centers | 3 | 2019 | 2759 | 0.090 |
Why?
|
| Cell Cycle Proteins | 2 | 1999 | 3449 | 0.090 |
Why?
|
| Sex Factors | 1 | 2024 | 10554 | 0.090 |
Why?
|
| Cross-Linking Reagents | 3 | 2003 | 687 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 5 | 1993 | 7406 | 0.090 |
Why?
|
| Cyclohexanols | 1 | 1990 | 126 | 0.090 |
Why?
|
| Protein Folding | 1 | 1994 | 870 | 0.090 |
Why?
|
| Erythropoietin | 1 | 1994 | 719 | 0.090 |
Why?
|
| Immunity, Cellular | 2 | 1993 | 1560 | 0.090 |
Why?
|
| Family | 2 | 2019 | 3195 | 0.080 |
Why?
|
| Medical Errors | 2 | 2009 | 1263 | 0.080 |
Why?
|
| Iron Chelating Agents | 1 | 1990 | 141 | 0.080 |
Why?
|
| Cell Division | 5 | 2000 | 4465 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 3 | 1998 | 1802 | 0.080 |
Why?
|
| Drug Industry | 1 | 2016 | 788 | 0.080 |
Why?
|
| Tubulin | 1 | 1993 | 693 | 0.080 |
Why?
|
| Cells, Cultured | 9 | 2003 | 18966 | 0.080 |
Why?
|
| Female | 23 | 2024 | 392705 | 0.080 |
Why?
|
| DNA, Complementary | 2 | 2003 | 1991 | 0.080 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2000 | 181 | 0.080 |
Why?
|
| Health Services | 1 | 2014 | 752 | 0.080 |
Why?
|
| Faculty, Medical | 1 | 2017 | 1204 | 0.080 |
Why?
|
| Anemia, Aplastic | 3 | 2001 | 230 | 0.080 |
Why?
|
| Research | 1 | 2017 | 1982 | 0.080 |
Why?
|
| Nursing Staff | 1 | 2009 | 113 | 0.080 |
Why?
|
| HLA Antigens | 3 | 1989 | 1328 | 0.080 |
Why?
|
| Multiple Sclerosis | 1 | 2023 | 3222 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 1990 | 1351 | 0.080 |
Why?
|
| Blotting, Northern | 3 | 2003 | 1545 | 0.080 |
Why?
|
| Immune Tolerance | 2 | 1994 | 2302 | 0.070 |
Why?
|
| Immunoblotting | 4 | 2003 | 1646 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2003 | 2748 | 0.070 |
Why?
|
| Cell Adhesion | 7 | 1993 | 3088 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 1999 | 2865 | 0.070 |
Why?
|
| Schools, Medical | 1 | 2014 | 879 | 0.070 |
Why?
|
| src Homology Domains | 2 | 1999 | 361 | 0.070 |
Why?
|
| Interviews as Topic | 3 | 2024 | 2696 | 0.070 |
Why?
|
| Membrane Proteins | 3 | 2003 | 7859 | 0.070 |
Why?
|
| B-Lymphocytes | 4 | 1993 | 4758 | 0.070 |
Why?
|
| Th2 Cells | 2 | 2005 | 1060 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 3 | 2003 | 5790 | 0.070 |
Why?
|
| Substrate Specificity | 2 | 2006 | 1791 | 0.070 |
Why?
|
| Genomics | 1 | 2023 | 5821 | 0.070 |
Why?
|
| Caregivers | 1 | 2019 | 2238 | 0.070 |
Why?
|
| Structure-Activity Relationship | 4 | 1995 | 3076 | 0.070 |
Why?
|
| Politics | 1 | 2014 | 815 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 1996 | 5112 | 0.070 |
Why?
|
| Thiazolidines | 1 | 2006 | 69 | 0.070 |
Why?
|
| Oncology Service, Hospital | 1 | 2007 | 57 | 0.070 |
Why?
|
| Bone Marrow | 2 | 1994 | 2911 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2017 | 2220 | 0.070 |
Why?
|
| Clone Cells | 6 | 2003 | 1659 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 1 | 1989 | 870 | 0.070 |
Why?
|
| Macromolecular Substances | 2 | 2002 | 1434 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 7828 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2002 | 3733 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 21019 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 2 | 2003 | 2645 | 0.060 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3206 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 1664 | 0.060 |
Why?
|
| Graft vs Tumor Effect | 1 | 2005 | 68 | 0.060 |
Why?
|
| Lymphokines | 2 | 2002 | 927 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2003 | 4576 | 0.060 |
Why?
|
| Quality of Life | 2 | 2024 | 13367 | 0.060 |
Why?
|
| Growth Substances | 2 | 2003 | 768 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 10212 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 473 | 0.060 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1989 | 547 | 0.060 |
Why?
|
| Erythrocytes | 3 | 1990 | 2413 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 477 | 0.060 |
Why?
|
| DNA Primers | 2 | 2001 | 2820 | 0.060 |
Why?
|
| Risk | 1 | 2017 | 9610 | 0.060 |
Why?
|
| Solubility | 1 | 2006 | 1091 | 0.060 |
Why?
|
| Cricetulus | 2 | 1998 | 814 | 0.060 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2007 | 395 | 0.060 |
Why?
|
| Male | 19 | 2024 | 360846 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 1998 | 1693 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2003 | 3779 | 0.060 |
Why?
|
| Graft Rejection | 3 | 1997 | 4446 | 0.060 |
Why?
|
| Education, Medical | 1 | 2015 | 1725 | 0.060 |
Why?
|
| Interleukin-4 | 2 | 2005 | 1149 | 0.060 |
Why?
|
| Dactinomycin | 1 | 2003 | 304 | 0.060 |
Why?
|
| Maprotiline | 1 | 1983 | 3 | 0.050 |
Why?
|
| Sheep | 3 | 1993 | 1440 | 0.050 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 3251 | 0.050 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 3 | 1998 | 489 | 0.050 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 2 | 1993 | 67 | 0.050 |
Why?
|
| Telemedicine | 1 | 2021 | 3052 | 0.050 |
Why?
|
| Health Personnel | 1 | 2017 | 3335 | 0.050 |
Why?
|
| Leukemia | 6 | 2001 | 1522 | 0.050 |
Why?
|
| Schools, Dental | 1 | 2024 | 123 | 0.050 |
Why?
|
| Thiazoles | 1 | 1990 | 1517 | 0.050 |
Why?
|
| Anthracenes | 1 | 1983 | 83 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2023 | 6845 | 0.050 |
Why?
|
| Endoplasmic Reticulum | 2 | 2003 | 1134 | 0.050 |
Why?
|
| Molecular Weight | 3 | 1996 | 2186 | 0.050 |
Why?
|
| Pseudopodia | 1 | 2003 | 168 | 0.050 |
Why?
|
| Pediatrics | 1 | 2018 | 3589 | 0.050 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 250 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 3 | 1995 | 1601 | 0.050 |
Why?
|
| Enzyme Inhibitors | 3 | 2000 | 3713 | 0.050 |
Why?
|
| Chemokine CCL3 | 1 | 2002 | 84 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 4 | 1998 | 2467 | 0.050 |
Why?
|
| Chemokine CCL4 | 1 | 2002 | 126 | 0.050 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2002 | 121 | 0.050 |
Why?
|
| Chromatography, Ion Exchange | 2 | 1992 | 297 | 0.050 |
Why?
|
| Glycosylation | 2 | 1996 | 1097 | 0.050 |
Why?
|
| Wiskott-Aldrich Syndrome | 3 | 1991 | 131 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2018 | 4652 | 0.050 |
Why?
|
| Tissue Distribution | 3 | 2003 | 2264 | 0.050 |
Why?
|
| Interleukin-16 | 1 | 2001 | 34 | 0.050 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2003 | 150 | 0.050 |
Why?
|
| Software | 1 | 2016 | 4434 | 0.050 |
Why?
|
| Publications | 1 | 2024 | 194 | 0.050 |
Why?
|
| Interleukin-1 | 2 | 2000 | 1248 | 0.050 |
Why?
|
| Binding Sites | 3 | 1996 | 6056 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 3462 | 0.050 |
Why?
|
| Depression | 1 | 2021 | 8126 | 0.050 |
Why?
|
| Binding, Competitive | 3 | 1992 | 1141 | 0.050 |
Why?
|
| Golgi Apparatus | 1 | 2003 | 405 | 0.050 |
Why?
|
| Aspartic Acid | 2 | 1995 | 576 | 0.050 |
Why?
|
| Giant Cells | 1 | 2002 | 188 | 0.050 |
Why?
|
| Losartan | 1 | 2023 | 265 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2003 | 410 | 0.050 |
Why?
|
| Iran | 1 | 2024 | 737 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2002 | 316 | 0.050 |
Why?
|
| Chloroquine | 1 | 2022 | 274 | 0.050 |
Why?
|
| Frustration | 1 | 2020 | 22 | 0.050 |
Why?
|
| Time Factors | 7 | 2024 | 39969 | 0.050 |
Why?
|
| Epitopes | 2 | 2003 | 2503 | 0.050 |
Why?
|
| STAT5 Transcription Factor | 1 | 2001 | 265 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2018 | 4811 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2014 | 3600 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2001 | 2872 | 0.050 |
Why?
|
| Chemokines, CXC | 1 | 2002 | 422 | 0.050 |
Why?
|
| Cyclosporins | 2 | 1991 | 216 | 0.040 |
Why?
|
| Bibliometrics | 1 | 2024 | 352 | 0.040 |
Why?
|
| Tachycardia | 1 | 1983 | 600 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2001 | 120 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2003 | 815 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 23996 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 1999 | 1841 | 0.040 |
Why?
|
| Cell Compartmentation | 1 | 2000 | 384 | 0.040 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2002 | 502 | 0.040 |
Why?
|
| Microtubule Proteins | 1 | 1999 | 62 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 719 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2002 | 696 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 2 | 1992 | 5672 | 0.040 |
Why?
|
| Yeasts | 1 | 2000 | 279 | 0.040 |
Why?
|
| European Union | 1 | 2020 | 157 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2024 | 2280 | 0.040 |
Why?
|
| Ionomycin | 2 | 1996 | 110 | 0.040 |
Why?
|
| Chromosome Segregation | 1 | 2000 | 235 | 0.040 |
Why?
|
| Cell Extracts | 1 | 1999 | 135 | 0.040 |
Why?
|
| Quality of Health Care | 2 | 2015 | 4331 | 0.040 |
Why?
|
| Nocodazole | 1 | 1998 | 95 | 0.040 |
Why?
|
| Outpatients | 1 | 2007 | 1597 | 0.040 |
Why?
|
| Infant | 2 | 2019 | 36193 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2003 | 3094 | 0.040 |
Why?
|
| Phospholipase C gamma | 1 | 1999 | 131 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2001 | 457 | 0.040 |
Why?
|
| Adipocytes | 2 | 1995 | 1194 | 0.040 |
Why?
|
| Community Health Centers | 1 | 2022 | 461 | 0.040 |
Why?
|
| Health Communication | 1 | 2021 | 213 | 0.040 |
Why?
|
| Zinc Fingers | 1 | 2001 | 579 | 0.040 |
Why?
|
| Multigene Family | 1 | 2001 | 1076 | 0.040 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1998 | 39 | 0.040 |
Why?
|
| Receptor Aggregation | 2 | 1995 | 72 | 0.040 |
Why?
|
| Type C Phospholipases | 1 | 1999 | 287 | 0.040 |
Why?
|
| Models, Biological | 3 | 2002 | 9469 | 0.040 |
Why?
|
| Mitogens | 1 | 1998 | 230 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2000 | 4352 | 0.040 |
Why?
|
| Sphingosine | 1 | 2000 | 308 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 1999 | 13642 | 0.040 |
Why?
|
| Immunotherapy, Active | 1 | 1998 | 59 | 0.040 |
Why?
|
| Coercion | 1 | 2018 | 69 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2002 | 1529 | 0.040 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1997 | 38 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 1003 | 0.040 |
Why?
|
| Clofazimine | 1 | 1997 | 41 | 0.040 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 1998 | 332 | 0.030 |
Why?
|
| Cell Size | 1 | 1999 | 624 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 1792 | 0.030 |
Why?
|
| DNA Mutational Analysis | 3 | 1990 | 4111 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 1999 | 392 | 0.030 |
Why?
|
| Protein Conformation | 2 | 2003 | 3968 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2001 | 664 | 0.030 |
Why?
|
| Proline | 1 | 1998 | 457 | 0.030 |
Why?
|
| Caspase 3 | 1 | 1999 | 731 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2023 | 1039 | 0.030 |
Why?
|
| Flow Cytometry | 3 | 1994 | 5870 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1516 | 0.030 |
Why?
|
| Financing, Government | 1 | 2020 | 472 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 1406 | 0.030 |
Why?
|
| Exocytosis | 2 | 1995 | 320 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1998 | 891 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2024 | 2209 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2024 | 1520 | 0.030 |
Why?
|
| Caspases | 1 | 1999 | 879 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 2 | 1994 | 262 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 1246 | 0.030 |
Why?
|
| Threonine | 1 | 1996 | 271 | 0.030 |
Why?
|
| Leukemia, T-Cell | 1 | 1995 | 101 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 1996 | 426 | 0.030 |
Why?
|
| Asparagine | 1 | 1995 | 119 | 0.030 |
Why?
|
| Liver Failure | 1 | 1997 | 250 | 0.030 |
Why?
|
| Emergencies | 1 | 2021 | 1217 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2330 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 1999 | 910 | 0.030 |
Why?
|
| Viral Vaccines | 1 | 2020 | 596 | 0.030 |
Why?
|
| Thymus Gland | 3 | 1994 | 1243 | 0.030 |
Why?
|
| Rwanda | 1 | 2017 | 665 | 0.030 |
Why?
|
| Leukemia, Myeloid | 1 | 1998 | 694 | 0.030 |
Why?
|
| Health Resources | 1 | 2021 | 935 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 236 | 0.030 |
Why?
|
| Calmodulin | 1 | 1995 | 218 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2021 | 2707 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 3810 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 695 | 0.030 |
Why?
|
| Molecular Mimicry | 1 | 1995 | 213 | 0.030 |
Why?
|
| Adult | 16 | 2024 | 221210 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1999 | 1687 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 3 | 2005 | 6214 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1992 | 1058 | 0.030 |
Why?
|
| Membrane Fluidity | 2 | 1995 | 68 | 0.030 |
Why?
|
| Virus Replication | 1 | 2002 | 2435 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 4 | 1997 | 1394 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 1998 | 2016 | 0.030 |
Why?
|
| beta Catenin | 1 | 1999 | 1040 | 0.030 |
Why?
|
| Spleen Focus-Forming Viruses | 1 | 1993 | 16 | 0.030 |
Why?
|
| Th1 Cells | 1 | 1999 | 1036 | 0.030 |
Why?
|
| Friend murine leukemia virus | 1 | 1993 | 37 | 0.030 |
Why?
|
| Androstadienes | 1 | 1995 | 348 | 0.030 |
Why?
|
| Antigen-Antibody Reactions | 2 | 1995 | 340 | 0.030 |
Why?
|
| Rosette Formation | 1 | 1993 | 152 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 2 | 1997 | 1036 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 416 | 0.030 |
Why?
|
| Lymphocyte Cooperation | 1 | 1993 | 112 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2003 | 3442 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1983 | 2244 | 0.030 |
Why?
|
| Prazosin | 1 | 1992 | 95 | 0.030 |
Why?
|
| Cell Membrane | 4 | 1991 | 3687 | 0.030 |
Why?
|
| Comprehension | 1 | 2018 | 621 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1993 | 851 | 0.030 |
Why?
|
| Mutation | 2 | 1995 | 30053 | 0.030 |
Why?
|
| Azides | 1 | 1992 | 118 | 0.030 |
Why?
|
| Forecasting | 1 | 2021 | 2928 | 0.030 |
Why?
|
| Daunorubicin | 1 | 1992 | 157 | 0.030 |
Why?
|
| Gentamicins | 1 | 1993 | 243 | 0.030 |
Why?
|
| Escherichia coli | 2 | 1996 | 4217 | 0.030 |
Why?
|
| Antigen-Antibody Complex | 1 | 1994 | 510 | 0.030 |
Why?
|
| Deamino Arginine Vasopressin | 3 | 1982 | 87 | 0.020 |
Why?
|
| Lymphoma | 1 | 2001 | 1901 | 0.020 |
Why?
|
| HTLV-I Infections | 1 | 1992 | 103 | 0.020 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1992 | 317 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2000 | 3162 | 0.020 |
Why?
|
| Bone Marrow Purging | 1 | 1991 | 108 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1993 | 490 | 0.020 |
Why?
|
| Phenotype | 4 | 1992 | 16592 | 0.020 |
Why?
|
| India | 1 | 2018 | 2348 | 0.020 |
Why?
|
| Middle Aged | 13 | 2024 | 220921 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 768 | 0.020 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1992 | 189 | 0.020 |
Why?
|
| Point Mutation | 1 | 1996 | 1595 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 2805 | 0.020 |
Why?
|
| Treatment Outcome | 7 | 2024 | 64685 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 779 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 1998 | 7593 | 0.020 |
Why?
|
| Inositol Phosphates | 1 | 1991 | 176 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1993 | 783 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 1993 | 1310 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 2 | 1992 | 562 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1993 | 461 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 1997 | 799 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 5493 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 3889 | 0.020 |
Why?
|
| Deferoxamine | 1 | 1990 | 155 | 0.020 |
Why?
|
| Arginine Vasopressin | 2 | 1980 | 125 | 0.020 |
Why?
|
| Antibodies | 1 | 1998 | 2418 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 1998 | 1051 | 0.020 |
Why?
|
| Feedback | 1 | 2014 | 791 | 0.020 |
Why?
|
| Ricin | 1 | 1990 | 70 | 0.020 |
Why?
|
| Solutions | 1 | 1990 | 412 | 0.020 |
Why?
|
| Mitochondria | 1 | 2003 | 3624 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 1998 | 1351 | 0.020 |
Why?
|
| Integrins | 1 | 1994 | 834 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1990 | 212 | 0.020 |
Why?
|
| Bone Marrow Cells | 3 | 1992 | 2417 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 1990 | 574 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1983 | 6377 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 1992 | 371 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 4016 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1997 | 1378 | 0.020 |
Why?
|
| Immunotoxins | 1 | 1990 | 175 | 0.020 |
Why?
|
| Transplantation, Homologous | 4 | 2001 | 4807 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 1990 | 544 | 0.020 |
Why?
|
| Steroids | 1 | 1994 | 929 | 0.020 |
Why?
|
| Pokeweed Mitogens | 1 | 1988 | 38 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 1993 | 964 | 0.020 |
Why?
|
| Massachusetts | 1 | 2022 | 8833 | 0.020 |
Why?
|
| Receptors, HIV | 1 | 1989 | 159 | 0.020 |
Why?
|
| Ribosomes | 1 | 1992 | 501 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1998 | 2822 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1992 | 535 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 1992 | 1031 | 0.020 |
Why?
|
| Colony-Stimulating Factors | 1 | 1989 | 218 | 0.020 |
Why?
|
| Hyponatremia | 2 | 1982 | 279 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 2578 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 1995 | 1502 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 3358 | 0.020 |
Why?
|
| Lymphocyte Depletion | 3 | 2001 | 602 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1988 | 364 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 2688 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1992 | 1757 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 3 | 1982 | 1063 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 1997 | 11742 | 0.020 |
Why?
|
| Interleukins | 1 | 1993 | 782 | 0.020 |
Why?
|
| Membrane Lipids | 1 | 1989 | 252 | 0.020 |
Why?
|
| Acute Disease | 2 | 1998 | 7237 | 0.020 |
Why?
|
| Thiocyanates | 1 | 1987 | 70 | 0.020 |
Why?
|
| Tissue Donors | 3 | 2005 | 2332 | 0.020 |
Why?
|
| Fluoresceins | 1 | 1987 | 235 | 0.020 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1987 | 223 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1997 | 2273 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 1997 | 5672 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1993 | 6075 | 0.020 |
Why?
|
| Amino Acids | 1 | 1993 | 1718 | 0.020 |
Why?
|
| Sodium | 3 | 1982 | 1588 | 0.020 |
Why?
|
| Pancreas | 1 | 1993 | 1691 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1994 | 2932 | 0.020 |
Why?
|
| Molecular Structure | 1 | 1990 | 1880 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1994 | 1844 | 0.020 |
Why?
|
| HLA-D Antigens | 1 | 1986 | 129 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1993 | 1374 | 0.020 |
Why?
|
| Carmustine | 2 | 1997 | 138 | 0.020 |
Why?
|
| Diffusion | 1 | 1987 | 814 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 1997 | 2330 | 0.020 |
Why?
|
| Ligands | 2 | 1991 | 3272 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2020 | 3802 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1989 | 1596 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 1995 | 3208 | 0.020 |
Why?
|
| Liposomes | 1 | 1988 | 783 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1989 | 1435 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1995 | 4740 | 0.010 |
Why?
|
| Parents | 1 | 2018 | 3563 | 0.010 |
Why?
|
| beta-N-Acetylhexosaminidases | 2 | 1995 | 44 | 0.010 |
Why?
|
| Etoposide | 2 | 1997 | 634 | 0.010 |
Why?
|
| Cell Differentiation | 3 | 1995 | 11530 | 0.010 |
Why?
|
| DNA | 3 | 1993 | 7213 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 1993 | 2050 | 0.010 |
Why?
|
| Cyclophosphamide | 3 | 1997 | 2220 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1988 | 1526 | 0.010 |
Why?
|
| Whole-Body Irradiation | 2 | 1998 | 433 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1993 | 3396 | 0.010 |
Why?
|
| Chronic Disease | 2 | 1997 | 9319 | 0.010 |
Why?
|
| Aged | 5 | 2024 | 169310 | 0.010 |
Why?
|
| Genes | 1 | 1987 | 1823 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 1986 | 423 | 0.010 |
Why?
|
| Methotrexate | 2 | 2001 | 1719 | 0.010 |
Why?
|
| Combined Modality Therapy | 4 | 1997 | 8527 | 0.010 |
Why?
|
| Disease-Free Survival | 3 | 1997 | 6815 | 0.010 |
Why?
|
| HIV | 1 | 1989 | 1582 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1989 | 1349 | 0.010 |
Why?
|
| RNA | 1 | 1992 | 2725 | 0.010 |
Why?
|
| Iron | 1 | 1990 | 1793 | 0.010 |
Why?
|
| Internet | 1 | 2014 | 3093 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 1990 | 2201 | 0.010 |
Why?
|
| Ganglionic Stimulants | 1 | 2000 | 18 | 0.010 |
Why?
|
| Cell Survival | 1 | 1991 | 5791 | 0.010 |
Why?
|
| Hydroquinones | 1 | 2000 | 34 | 0.010 |
Why?
|
| Plants, Toxic | 1 | 2000 | 71 | 0.010 |
Why?
|
| Catechols | 1 | 2000 | 62 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1990 | 3769 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 26129 | 0.010 |
Why?
|
| Perception | 1 | 2007 | 1197 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1986 | 974 | 0.010 |
Why?
|
| Adolescent | 8 | 2001 | 88326 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2007 | 2426 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2001 | 712 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1987 | 1903 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1986 | 783 | 0.010 |
Why?
|
| Cell Movement | 1 | 1991 | 5205 | 0.010 |
Why?
|
| Smoke | 1 | 2000 | 235 | 0.010 |
Why?
|
| G1 Phase | 1 | 1999 | 403 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2018 | 26202 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 1998 | 363 | 0.010 |
Why?
|
| Neoplasms | 1 | 2007 | 22173 | 0.010 |
Why?
|
| Insulin | 1 | 1992 | 6597 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 2319 | 0.010 |
Why?
|
| Biological Products | 1 | 1986 | 914 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1988 | 4544 | 0.010 |
Why?
|
| Mice, Nude | 2 | 1998 | 3614 | 0.010 |
Why?
|
| Hemoglobin, Sickle | 3 | 1982 | 113 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 1998 | 565 | 0.010 |
Why?
|
| Survival Analysis | 2 | 2001 | 10090 | 0.010 |
Why?
|
| Ionophores | 1 | 1996 | 107 | 0.010 |
Why?
|
| Life Tables | 1 | 1996 | 364 | 0.010 |
Why?
|
| HIV Infections | 1 | 2002 | 17354 | 0.010 |
Why?
|
| Nicotine | 1 | 2000 | 680 | 0.010 |
Why?
|
| Biological Availability | 1 | 1996 | 390 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1998 | 1762 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1996 | 311 | 0.010 |
Why?
|
| Histocompatibility | 1 | 1996 | 317 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1994 | 114 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1996 | 532 | 0.010 |
Why?
|
| Fibronectins | 1 | 1998 | 723 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 1995 | 286 | 0.010 |
Why?
|
| Centrifugation, Isopycnic | 1 | 1993 | 8 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 1994 | 436 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1995 | 1085 | 0.010 |
Why?
|
| Boston | 1 | 2007 | 9327 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1986 | 2223 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1993 | 777 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 4853 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 1997 | 496 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1994 | 299 | 0.010 |
Why?
|
| Parity | 1 | 1996 | 927 | 0.010 |
Why?
|
| Antioxidants | 1 | 2000 | 1668 | 0.010 |
Why?
|
| Cytoplasmic Granules | 1 | 1995 | 574 | 0.010 |
Why?
|
| Genes, myc | 1 | 1993 | 390 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2001 | 1881 | 0.010 |
Why?
|
| Ribosomal Protein S6 | 1 | 1992 | 71 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1995 | 2180 | 0.010 |
Why?
|
| Survival Rate | 2 | 1997 | 12723 | 0.010 |
Why?
|
| Receptors, IgE | 1 | 1992 | 375 | 0.010 |
Why?
|
| Introns | 1 | 1993 | 981 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1992 | 412 | 0.010 |
Why?
|
| Erythrocytes, Abnormal | 2 | 1982 | 121 | 0.010 |
Why?
|
| Erythrocyte Indices | 2 | 1982 | 144 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 1997 | 1590 | 0.010 |
Why?
|
| Lymphocytes | 2 | 1989 | 2612 | 0.010 |
Why?
|
| Cattle | 1 | 1996 | 3849 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1991 | 602 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1994 | 1869 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1993 | 1232 | 0.010 |
Why?
|
| Cell Separation | 1 | 1994 | 1720 | 0.000 |
Why?
|
| Child, Preschool | 3 | 2001 | 42232 | 0.000 |
Why?
|
| Dogs | 1 | 1993 | 3839 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1990 | 641 | 0.000 |
Why?
|
| Recurrence | 2 | 1997 | 8466 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1993 | 2115 | 0.000 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1991 | 1126 | 0.000 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1991 | 531 | 0.000 |
Why?
|
| Cytarabine | 1 | 1990 | 698 | 0.000 |
Why?
|
| Exons | 1 | 1993 | 2391 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2005 | 22174 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1994 | 5035 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 2001 | 12341 | 0.000 |
Why?
|
| Prospective Studies | 2 | 2007 | 54423 | 0.000 |
Why?
|
| Glycosides | 1 | 1987 | 100 | 0.000 |
Why?
|
| Antifungal Agents | 1 | 1991 | 753 | 0.000 |
Why?
|
| Prostaglandins E | 1 | 1986 | 166 | 0.000 |
Why?
|
| Gene Deletion | 1 | 1993 | 2665 | 0.000 |
Why?
|
| Indomethacin | 1 | 1986 | 325 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1996 | 2091 | 0.000 |
Why?
|
| Oxygen | 3 | 1982 | 4227 | 0.000 |
Why?
|
| Calcitonin | 1 | 1986 | 329 | 0.000 |
Why?
|
| Prognosis | 2 | 1997 | 29629 | 0.000 |
Why?
|
| Culture Media | 1 | 1986 | 897 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 12059 | 0.000 |
Why?
|
| Dinoprostone | 1 | 1986 | 597 | 0.000 |
Why?
|
| Biological Assay | 1 | 1986 | 626 | 0.000 |
Why?
|
| Bone Resorption | 1 | 1986 | 723 | 0.000 |
Why?
|
| Models, Molecular | 1 | 1991 | 5439 | 0.000 |
Why?
|
| Graft Survival | 1 | 1991 | 3820 | 0.000 |
Why?
|
| Water-Electrolyte Balance | 1 | 1982 | 325 | 0.000 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1982 | 292 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1993 | 11076 | 0.000 |
Why?
|
| Parathyroid Hormone | 1 | 1986 | 1803 | 0.000 |
Why?
|
| Monocytes | 1 | 1987 | 2570 | 0.000 |
Why?
|
| Incidence | 1 | 1996 | 21355 | 0.000 |
Why?
|
| Risk Factors | 2 | 1997 | 74213 | 0.000 |
Why?
|
| Fluid Therapy | 1 | 1980 | 579 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 1994 | 5146 | 0.000 |
Why?
|
| Brain | 1 | 1996 | 27121 | 0.000 |
Why?
|